Related Experiment Videos
Plasma somatomedin-C levels in systemic sclerosis.
M J Rothe1, R D Altman, V Falanga
1Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Florida 33101.
The British Journal of Dermatology
|November 1, 1988
Summary
Plasma levels of insulin-like growth factor I (IGF-I) were normal in patients with progressive systemic sclerosis (PSS). This suggests PSS pathogenesis may involve fibroblast receptors or responses to IGF-I, not circulating levels.
Area of Science:
- Endocrinology
- Rheumatology
- Cell Biology
Background:
- Progressive systemic sclerosis (PSS) is an autoimmune disease characterized by fibrosis.
- Insulin-like growth factor I (IGF-I), also known as somatomedin-C (SM-C), is a key regulator of cell growth and differentiation.
- The role of IGF-I in PSS pathogenesis is not fully understood.
Purpose of the Study:
- To investigate the plasma levels of IGF-I (SM-C) in patients with PSS.
- To explore the potential involvement of IGF-I in the development of PSS.
Main Methods:
- Plasma samples were collected from 13 patients diagnosed with PSS.
- Plasma samples were also collected from age- and sex-matched healthy controls.
- Plasma concentrations of IGF-I (SM-C) were measured using established assays.
Main Results:
- All patients with PSS exhibited plasma IGF-I (SM-C) levels within the normal range.
- No significant difference in plasma IGF-I levels was observed between PSS patients and healthy controls.
Conclusions:
- Circulating plasma levels of IGF-I (SM-C) do not appear to be a significant factor in the pathogenesis of PSS.
- The potential role of IGF-I in PSS may be related to fibroblast receptor interactions or intracellular signaling pathways rather than systemic levels.